EGFR and non-small cell lung carcinoma: EGFR-targeting tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and osimertinib, extend median progression-free survival (PFS) and overall survival (OS) in NSCLC patients with EGFR mutations (6, 7).